Anti-Cancer Effects of Oxygen-Atom-Modified Derivatives of Wasabi Components on Human Leukemia Cells
Open Access
- 6 April 2023
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6823
Abstract
1-Isothiocyanato-6-(methylsulfinyl)-hexanate (6-MITC) is a natural compound found in Wasabia japonica. The synthetic derivatives 1-Isothiocyanato-6-(methylsulfenyl)-hexane (I7447) and 1-Isothiocyanato-6-(methylsulfonyl)-hexane (I7557) were obtained from 6-MITC by deleting and adding an oxygen atom to the sulfone group, respectively. We previously demonstrated that extensive mitotic arrest, spindle multipolarity, and cytoplasmic vacuole accumulation were induced by 6-MITC and inhibited the viability of human chronic myelogenous leukemia K562 cells. In this study, we examined the anti-cancer effects of 6-MITC derivatives on human chronic myelogenous leukemia (CML) cells. Autophagy was identified as the formation of autophagosomes with double-layered membranes using transmission electron microscopy. Cell cycle and differentiation were analyzed using flow cytometry. Apoptosis was detected by annexin V staining. After treatment with I7447 and I7557, the G2/M phase of cell cycle arrest was revealed. Cell death can be induced by a distinct mechanism (the simultaneous occurrence of autophagy and aberrant mitosis). The expression levels of acridine orange were significantly affected by lysosomal inhibitors. The natural wasabi component, 6-MITC, and its synthetic derivatives have similar effects on human chronic myelogenous leukemia cells and may be developed as novel therapeutic agents against leukemia.Keywords
Funding Information
- Mackay Memorial Hospital (MMH-E-111-11, MMH-E-110-13, MOST 109-2314+B-195-003-MY3)
- Ministry of Science and Technology, Taiwan (MMH-E-111-11, MMH-E-110-13, MOST 109-2314+B-195-003-MY3)
This publication has 54 references indexed in Scilit:
- Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapyHaematologica, 2011
- Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaLeukemia, 2009
- Autophagy in the Pathogenesis of DiseaseCell, 2008
- Dasatinib: a new step in molecular target therapyAnnals of Oncology, 2007
- Preventive effect of oral administration of 6-(methylsulfinyl)hexyl isothiocyanate derived from wasabi (Wasabia japonica Matsum) against pulmonary metastasis of B16-BL6 mouse melanoma cellsCancer Detection Prevention, 2006
- Selective sensitivity to wasabi-derived 6-(methylsulfinyl)hexyl isothiocyanate of human breast cancer and melanoma cell lines studied in vitroCancer Detection Prevention, 2005
- Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome–positive chronic-phase chronic myeloid leukemia after failure of interferon-αBlood, 2004
- Chronic Myeloid Leukemia — Advances in Biology and New Approaches to TreatmentNew England Journal of Medicine, 2003
- Fc gamma receptor III on human neutrophils. Allelic variants have functionally distinct capacities.Journal of Clinical Investigation, 1990
- A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa StainingNature, 1973